Global Community

PayPal is trying to shake off years of disappointment by rebuilding its checkout experience and pushing into new ways to pay, from smarter shopping tools to its own digital dollar. The bigger question is whether these bets can reignite customer and merchant momentum fast enough in a crowded payments market.Read more

A tiny explorer near a major Balkan mining deal could become Europe’s first homegrown source of a metal the West is scrambling to secure as export restrictions loom. The upside comes with real danger: it’s an early-stage, thinly traded bet that depends on more people noticing what its drill results suggest.Read more

The Auction Business Moat Is Fine. The Capital Allocation Is Not.Read more

A little-known UK software firm is already helping hospitals, councils, and banks automate everyday tasks using AI, yet the market still treats it like ordinary workflow software. See why its deep roots in public services could drive years of growth—and how big tech rivals could spoil the story.Read more

LVMH faces a demand slowdown, but the business keeps growing as it adds brands, expands its hotel footprint, and leans into high-end categories. If the market is judging the company on the recent dip while it keeps building for the long run, this could be a rare moment when a luxury leader looks undervalued.Read more

Rezolve AI wants to turn shopping chats into completed purchases, handling everything from questions to checkout in one conversation. The upside is big if retailers adopt this approach quickly—but it hinges on execution and whether giants like Amazon or Shopify decide to build their own version.Read more

Charter is finishing a costly network upgrade, and the business could soon throw off a lot more cash that it can use to shrink debt and buy back shares. Even with slow customer growth, the author argues the market is overlooking hidden value in the company’s debt and the potential upside from a deal or partnership buzz.Read more

Saudi Ground Services goes from near-monopoly to a more open market, and the share price already reflects a lot of fear about new rivals. The key question is whether its long-standing airline contracts and cash-rich, low-investment business can keep dividends and profits steady as competition ramps up.Read more

Many investors treat Kuros Biosciences like a risky drug developer, but the company now makes a bone-graft product that aims to help hospitals get similar patient results while spending less. The story hinges on surgery centers shifting toward lower-cost care, Kuros’s control over its key technology, and a few practical risks that could slow adoption.Read more